CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Katrijn Bogman (ORCID: https://orcid.org/0000-0003-2191-4461)
- Martina Wollenhaupt
- Brian B. Berger (ORCID: https://orcid.org/0000-0002-8639-1756)
- Nikolaos Mitrousis (ORCID: https://orcid.org/0000-0002-6451-5180)
- Beatriz Garcia Armendariz (ORCID: https://orcid.org/0000-0001-5473-8164)
- Andreas Wenzel (ORCID: https://orcid.org/0000-0002-2758-9842)
- David Kent
- Jules Hernandez-Sanchez
- Sascha Fauser
- Ulrich F.O. Luhman
Institutions
- Roche (Switzerland) (CH)
- Roche (United Kingdom) (GB)
- Houston Institute for Clinical Research (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.xops.2024.100650
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Roche
- F. Hoffmann-La Roche